Compare StocksHCA vs PFE

HCA Healthcare, Inc. (HCA) vs Pfizer Inc. (PFE): Which Is the Better Buy in 2026?

As of 2026-06-19, HCA is undervalued at $375, with a DCF intrinsic value of $523 and a margin of safety of 28%. PFE is overvalued at $25, with an intrinsic value of $22 and a margin of safety of -12%. Of the two, HCA has the wider margin of safety.

HCA
HCA Healthcare, Inc.
$375.17
VS
PFE
Pfizer Inc.
$25.21

Rewards

HCA
  • HCA Healthcare, Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • HCA Healthcare, Inc. scores 95/100 on the Economic Moat Score (Wide Moat), with roic consistency as the strongest competitive dimension.
  • Free cash flow has grown at a 23.1% CAGR over the past 4 years, demonstrating strong earnings power growth.
PFE
  • Gross margin of 74.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • FCF yield of 8.6% is historically attractive — the business generates significant cash relative to its price.
  • Trailing P/E of 19.2x is 37% below the historical average of 30.4x — potentially undervalued relative to its own history.

Risks

HCA
    PFE
    • ROIC has declined by 15.9 percentage points over the past 4 years, which may signal competitive erosion.
    • PEG ratio of 13.77 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
    • Free cash flow has declined at a 29.6% CAGR over the past 4 years — a concerning trend.

    Key Valuation Metrics

    Learn more →
    HCA
    PFE
    Valuation
    $7.69B
    Free Cash Flow
    $12.38B
    9.24%
    FCF Yield
    8.61%
    12.93
    Trailing P/E
    19.24
    11.33
    Forward P/E
    8.91
    Quality & Moat
    18.14%
    ROIC
    10.19%
    N/A
    ROE
    8.31%
    41.61%
    Gross Margin
    74.80%
    1.20
    PEG Ratio
    13.77
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    0.57
    N/A
    Interest Coverage
    N/A
    3.13
    Net Debt / EBITDA
    2.03
    0.76%
    Dividend Yield
    6.61%
    HCA: 4Ties: 1PFE: 5
    HCAPFE

    Historical Fundamentals

    Learn more →
    HCA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    PFE

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    HCA
    $2.43
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $15.76B
    Δ Market Cap
    +$38.30B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    PFE
    N/A
    Net losses over 3 years — test not applicable
    Company had negative cumulative retained earnings
    Σ Retained
    $-10.61B
    Δ Market Cap
    $-146.18B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    HCA
    28.2% Margin of Safety
    Price is 28.2% below estimated fair value
    Current Price: $375.17
    Fair Value: $522.55
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    PFE
    12.3% Overvalued
    Price is 12.3% above estimated fair value
    Current Price: $25.21
    Fair Value: $22.46
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    HCA

    What growth rate is the market pricing in at $375?

    +7.3%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +5.6%

    The market implies +7.3% Owner Earnings growth, roughly in line with history — reasonably priced.

    Standard FCF implies +5.6%, reflecting ongoing growth investment.

    PFE

    What growth rate is the market pricing in at $25?

    +5.2%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +4.5%

    The market implies +5.2% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +4.5%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    HCA
    95/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. ROIC Consistency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    PFE
    35/100
    No Moat
    70+ Wide · 40-69 Narrow · <40 None

    No durable moat detected, though reinvestment efficiency shows some competitive positioning. The business lacks consistent evidence of sustainable advantages.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    HCA
    -2.78
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    PFE
    -2.53
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    HCA
    Insiders 16.2%Institutions 78.3%Retail & Other 5.5%
    No. of Institutional Holders1,952
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    PFE
    Insiders 0.1%Institutions 69.4%Retail & Other 30.5%
    No. of Institutional Holders3,744
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    HCA
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    PFE
    0
    Buys (3M)
    0
    Buys (12M)
    BLAYLOCK RONALD E
    Director
    $499,072
    @ $25.65 · 2025-02-13
    GOTTLIEB SCOTT
    Director
    $28,240
    @ $28.24 · 2024-10-30
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    HCA
    0
    Sells (3M)
    7
    Sells (12M)
    Total value (12M): $32.73M
    MCALEVEY MICHAEL R.
    Officer
    $903,537
    @ $533.37 · 2026-02-18
    WYATT CHRISTOPHER F
    Officer
    $2.02M
    @ $505.00 · 2026-02-11
    BERRES JENNIFER
    Officer
    $4.13M
    @ $514.58 · 2026-02-11
    HAZEN SAMUEL N
    Chief Executive Officer
    $21.48M
    @ $501.04 · 2026-02-03
    CUFFE MICHAEL S
    Officer
    $747,135
    @ $498.09 · 2026-02-03
    MCALEVEY MICHAEL R.
    Officer
    $1.84M
    @ $473.79 · 2025-11-05
    CUFFE MICHAEL S
    Officer
    $1.61M
    @ $418.84 · 2025-09-08
    FOSTER JON MARK
    Officer
    $5.80M
    @ $369.32 · 2025-05-13
    BERRES JENNIFER
    Officer
    $3.08M
    @ $322.59 · 2025-02-14
    BILLINGTON PHILLIP G
    Officer
    $1.36M
    @ $350.00 · 2024-11-14
    WHALEN KATHLEEN M
    Officer
    $527,677
    @ $357.99 · 2024-11-14
    AKDAMAR EROL R
    Officer
    $1.02M
    @ $353.00 · 2024-11-14
    CUFFE MICHAEL S
    Officer
    $3.22M
    @ $385.42 · 2024-09-12
    WHALEN KATHLEEN M
    Officer
    $1.76M
    @ $362.13 · 2024-07-31
    WYATT CHRISTOPHER F
    Officer
    $1.44M
    @ $360.20 · 2024-07-29
    REINER DEBORAH M
    Officer
    $1.19M
    @ $359.96 · 2024-07-29
    TORRES KATHRYN A
    Officer
    $659,328
    @ $355.05 · 2024-07-25
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    PFE
    1
    Sells (3M)
    1
    Sells (12M)
    Total value (12M): $51,400
    DAMICO JENNIFER B.
    Officer
    $51,400
    @ $25.70 · 2026-06-09
    DAMICO JENNIFER B.
    Officer
    $64,825
    @ $25.93 · 2025-03-04
    DAMICO JENNIFER B.
    Officer
    $147,714
    @ $28.66 · 2024-08-13
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    HCA
    FearGreed
    😨Fear(39/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    PFE
    FearGreed
    😐Neutral(49/100)

    "Market is pricing this stock without strong emotion in either direction"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    HCA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (39)
    PFE
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Neutral (49)
    View HCA Full AnalysisView PFE Full Analysis

    Frequently Asked Questions: HCA vs PFE

    Is HCA Healthcare, Inc. or Pfizer Inc. more undervalued in 2026?

    Based on our discounted cash flow model, HCA trades at a 28.2% margin of safety (intrinsic value $523 vs. price $375), compared to PFE's -12.3% margin of safety (intrinsic $22 vs. $25).

    Which stock has a wider economic moat, HCA Healthcare, Inc. or Pfizer Inc.?

    HCA scores 95/100 (Wide moat), while PFE scores 35/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is Pfizer Inc. in financial distress?

    PFE's Altman Z-Score of 2.1 places it in the Grey zone, signaling elevated bankruptcy risk. HCA scores 2.7 (Grey zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, HCA Healthcare, Inc. or Pfizer Inc.?

    HCA Healthcare, Inc. (HCA) generates a 9.2% free cash flow yield, compared to Pfizer Inc.'s 8.6%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, HCA Healthcare, Inc. or Pfizer Inc.?

    HCA earns 18.1% ROIC versus PFE's 10.2%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, HCA Healthcare, Inc.'s or Pfizer Inc.'s?

    HCA's dividend earns a safety score of 94/100 (Very Safe), compared to PFE's 24/100 (Unsafe). HCA has raised its dividend for 3 consecutive years.